Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of “Hold” by Brokerages

Shares of Illumina, Inc. (NASDAQ:ILMN) have received a consensus rating of “Hold” from the twenty brokerages that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $123.3333.

Several research analysts have commented on the company. Royal Bank Of Canada set a $124.00 target price on Illumina in a report on Tuesday, September 2nd. Scotiabank lowered Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price objective on the stock. in a research note on Friday, July 11th. Stephens set a $110.00 target price on shares of Illumina and gave the company an “overweight” rating in a research report on Monday, August 4th. Weiss Ratings restated a “sell (d+)” rating on shares of Illumina in a report on Saturday, September 27th. Finally, Citigroup lowered shares of Illumina from a “hold” rating to a “strong sell” rating and reduced their price objective for the company from $85.00 to $80.00 in a research note on Wednesday, July 9th.

Illumina Trading Up 2.8%

ILMN opened at $102.12 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. Illumina has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The company’s 50 day moving average price is $99.07 and its two-hundred day moving average price is $89.85. The firm has a market capitalization of $15.70 billion, a price-to-earnings ratio of 12.93, a PEG ratio of 2.40 and a beta of 1.40.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the previous year, the business earned $0.36 earnings per share. Illumina’s revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, research analysts predict that Illumina will post 4.51 earnings per share for the current year.

Institutional Trading of Illumina

Large investors have recently bought and sold shares of the business. Rise Advisors LLC lifted its stake in shares of Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 224 shares during the period. Parkside Financial Bank & Trust lifted its stake in Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after buying an additional 115 shares during the period. Rakuten Securities Inc. boosted its holdings in shares of Illumina by 290.3% during the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock worth $29,000 after buying an additional 270 shares in the last quarter. Center for Financial Planning Inc. acquired a new stake in shares of Illumina during the 1st quarter worth approximately $33,000. Finally, PFS Partners LLC grew its position in shares of Illumina by 400.0% during the 1st quarter. PFS Partners LLC now owns 500 shares of the life sciences company’s stock worth $40,000 after buying an additional 400 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.